Brokerages expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to report $4.81 million in sales for the current quarter, Zacks reports. Four analysts have provided estimates for Five Prime Therapeutics’ earnings. The lowest sales estimate is $2.10 million and the highest is $7.50 million. Five Prime Therapeutics reported sales of $32.49 million during the same quarter last year, which would suggest a negative year over year growth rate of 85.2%. The business is expected to report its next earnings report on Tuesday, May 14th.
On average, analysts expect that Five Prime Therapeutics will report full year sales of $20.00 million for the current fiscal year, with estimates ranging from $7.30 million to $30.00 million. For the next year, analysts forecast that the firm will post sales of $51.67 million, with estimates ranging from $10.00 million to $150.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its earnings results on Tuesday, February 26th. The biotechnology company reported ($1.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.32) by $0.20. Five Prime Therapeutics had a negative return on equity of 44.55% and a negative net margin of 281.64%.
Several hedge funds and other institutional investors have recently made changes to their positions in FPRX. Quantamental Technologies LLC purchased a new position in shares of Five Prime Therapeutics in the 4th quarter worth approximately $58,000. Jane Street Group LLC purchased a new position in shares of Five Prime Therapeutics in the 4th quarter worth approximately $110,000. Virtu Financial LLC purchased a new position in shares of Five Prime Therapeutics in the 4th quarter worth approximately $113,000. Metropolitan Life Insurance Co. NY boosted its stake in shares of Five Prime Therapeutics by 456.2% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,283 shares of the biotechnology company’s stock worth $124,000 after buying an additional 10,895 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. purchased a new position in shares of Five Prime Therapeutics in the 4th quarter worth approximately $140,000. Hedge funds and other institutional investors own 86.30% of the company’s stock.
Shares of FPRX stock traded up $0.43 during mid-day trading on Friday, hitting $12.40. The company’s stock had a trading volume of 599,600 shares, compared to its average volume of 287,570. Five Prime Therapeutics has a 52 week low of $7.84 and a 52 week high of $19.95. The firm has a market cap of $423.04 million, a PE ratio of -3.00 and a beta of 3.16.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.
See Also: Dow Jones Industrial Average (DJIA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.